ClinicalTrials.gg
CompletedNCT00828919Updated Dec 3, 2024Results posted

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

An interventional study of axitinib and crizotinib in Solid Tumors, sponsored by Pfizer. Completed at 34 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Pfizer · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 10 months after the study started (first participant enrolled Mar 2003, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Read the detailed description

This is a roll over study aimed to provide continued access to axitinib (monotherapy or combination, according to treatment received in prior axitinib study) to patients who have documented stable, or responding disease, or received clinical benefit (as defined by protocol) at the time of the prior study closure.

02

Conditions studied

  • Solid Tumors

Keywords

  • VEGFR inhibitor
  • angi-angiogenic
  • tyrosine kinase inhibitor
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a previous clinical trial
  • Patients who were receiving axitinib (AG-013736) tablets at the time their previous trial ended
  • Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol should be used to determine stable or responding disease).
  • Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

Exclusion criteria

Exclusion Criteria:

  • Patients may not participate in this trial if the conditions for continuing treatment in the previous axitinib (AG-013736) protocol are not met
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Treatment

    Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study

    Drug: axitinib · Drug: crizotinib

Interventions

  • BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial

    Also known as: AG-013736

  • BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.

    Also known as: PF-02341066

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and non-serious AEs.

    Time frame: Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow-up to approximately 120.56 months)

07

Results

Posted Dec 3, 2024

Participant flow

A total of 52 participants were enrolled in this study, out of which 49 were treated. Enrollment for this study was planned to be conducted into two groups: Axitinib monotherapy and Axitinib combination therapy. However, no participant enrolled in Axitinib combination therapy group.

Participant flow — Overall Study
MilestoneAxitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOther
Started7920211
Completed00000
Not completed7920211
Withdrew: Death01200
Withdrew: Adverse event22213
Withdrew: Objective progression or relapse441105
Withdrew: No longer willing to participate in study00200
Withdrew: Insufficient clinical response01200
Withdrew: Subject refused continued treatment for reason other than adverse event00003
Withdrew: Other10110
Withdrew: Lost to follow-up01000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and non-serious AEs.

Time frame:
Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow-up to approximately 120.56 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs
ParticipantsOverallAxitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOther
TEAEs497920211
Serious TEAEs2148504
Treatment Related TEAEs477918211
Treatment Related Serious TEAEs1527303

Adverse events

Collected over Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow up to approximately 120.56 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall5/49 (10.2%)21/49 (42.9%)48/49 (98%)
Axitinib 2 mg1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Axitinib 3 mg1/9 (11.1%)8/9 (88.9%)9/9 (100%)
Axitinib 5 mg3/20 (15%)5/20 (25%)19/20 (95%)
Axitinib 7 mg0/2 (0%)0/2 (0%)2/2 (100%)
Other0/11 (0%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventOverallAxitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOther
Myocardial infarctionCardiac disorders6/490/75/90/200/21/11
Acute coronary syndromeCardiac disorders2/490/72/90/200/20/11
VomitingGastrointestinal disorders2/490/72/90/200/20/11
DehydrationMetabolism and nutrition disorders3/490/72/91/200/20/11
NeutropeniaBlood and lymphatic system disorders1/491/70/90/200/20/11
Acute myocardial infarctionCardiac disorders3/491/71/91/200/20/11
EnterocolitisGastrointestinal disorders1/491/70/90/200/20/11
Upper gastrointestinal haemorrhageGastrointestinal disorders1/491/70/90/200/20/11
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/491/70/90/200/20/11
DizzinessNervous system disorders1/491/70/90/200/20/11
Most frequent other events
Showing 10 of 211
Most frequent other events
EventOverallAxitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOther
DiarrhoeaGastrointestinal disorders30/493/79/910/202/26/11
NauseaGastrointestinal disorders11/491/73/92/202/23/11
FatigueGeneral disorders21/491/76/96/202/26/11
DysphoniaRespiratory, thoracic and mediastinal disorders9/492/70/93/202/22/11
HypertensionVascular disorders28/493/77/911/202/25/11
ProteinuriaRenal and urinary disorders14/495/71/95/200/23/11
Weight decreasedInvestigations17/491/75/97/201/23/11
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders19/491/75/97/201/25/11
HypothyroidismEndocrine disorders16/493/74/95/201/23/11
ConstipationGastrointestinal disorders6/490/72/91/201/22/11

Baseline characteristics

Safety population included all participants who received at least one dose of axitinib under A4061008 protocol.

Age, Continuous
Age, Continuous(Years)Axitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOtherTotal
Mean61.6 ± 14.757.1 ± 11.358.5 ± 4.268.5 ± 3.564.6 ± 8.660.4 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOtherTotal
Female2241514
Male57161635
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Axitinib 2 mgAxitinib 3 mgAxitinib 5 mgAxitinib 7 mgOtherTotal
American Indian or Alaska Native000000
Asian5240011
Native Hawaiian or Other Pacific Islander000000
Black or African American010001
White25142932
More than one race000000
Unknown or Not Reported012025
08

Study locations

34 sites
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • UCLA Hematology-Oncology-Santa Monica
    Santa Monica, California 90404, United States
  • University of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10022, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Providence Regional Medical Center Everett - Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
  • University of Wisconsin - Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Fakultni nemocnice Olomouc
    Olomouc, Czech Republic 77900, Czechia
  • Nemocnice Na Bulovce
    Praha, 18081, Czechia
  • Hopital de la Pitie Salpetriere
    Paris Cedex 13, 75651, France
  • Charité - Universitaetsmedizin Berlin, Charité Campus Mitte
    Berlin, 10117, Germany
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar
    Budapest, 1083, Hungary
  • Fondazione IRCCS, Istituto Nazionale Tumori, Laboratorio
    Milano, 20133, Italy
  • Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo
    Milano, 20133, Italy
  • Kinki University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • National Cancer Center Hospital East
    Kashiwa, Tiba 277-8577, Japan
  • Chiba Cancer Center
    Chiba, 260-8717, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • FSBSI "N.N. Blokhin Russian Cancer Research Center"
    Moscow, 115478, Russian Federation
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Nottingham City Hospital / Oncology Department
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2003 to primary completion in Aug 2023, 245 months.

Results were first posted in Dec 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2009
First posted
Jan 26, 2009
StartActual
Mar 7, 2003
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 14, 2023
Results first posted
Dec 3, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00828919
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 26, 2009
Start date
Mar 7, 2003
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Results posted
Dec 3, 2024
Last update
Dec 3, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion